SI3449934T1 - Zdravljenje bolezni kopičenja glikogena tip II - Google Patents

Zdravljenje bolezni kopičenja glikogena tip II

Info

Publication number
SI3449934T1
SI3449934T1 SI200131073T SI200131073T SI3449934T1 SI 3449934 T1 SI3449934 T1 SI 3449934T1 SI 200131073 T SI200131073 T SI 200131073T SI 200131073 T SI200131073 T SI 200131073T SI 3449934 T1 SI3449934 T1 SI 3449934T1
Authority
SI
Slovenia
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
SI200131073T
Other languages
English (en)
Slovenian (sl)
Inventor
Yuan-Tsong Chen
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3449934(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Publication of SI3449934T1 publication Critical patent/SI3449934T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200131073T 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tip II SI3449934T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
EP18194771.4A EP3449934B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
SI3449934T1 true SI3449934T1 (sl) 2020-09-30

Family

ID=22818451

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200131073T SI3449934T1 (sl) 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tip II
SI200131057A SI2767291T1 (sl) 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tipa II
SI200131068T SI3108895T1 (sl) 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tipa II

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200131057A SI2767291T1 (sl) 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tipa II
SI200131068T SI3108895T1 (sl) 2000-07-18 2001-07-10 Zdravljenje bolezni kopičenja glikogena tipa II

Country Status (17)

Country Link
US (10) US7056712B2 (cg-RX-API-DMAC7.html)
EP (4) EP3108895B1 (cg-RX-API-DMAC7.html)
JP (10) JP5113312B2 (cg-RX-API-DMAC7.html)
AT (1) ATE355075T1 (cg-RX-API-DMAC7.html)
AU (3) AU2001271941B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113006A (cg-RX-API-DMAC7.html)
CA (1) CA2416492C (cg-RX-API-DMAC7.html)
CY (2) CY1120977T1 (cg-RX-API-DMAC7.html)
DE (1) DE60126947T2 (cg-RX-API-DMAC7.html)
DK (5) DK3449934T3 (cg-RX-API-DMAC7.html)
ES (5) ES2277931T3 (cg-RX-API-DMAC7.html)
LT (3) LT3108895T (cg-RX-API-DMAC7.html)
MX (1) MXPA03000474A (cg-RX-API-DMAC7.html)
PT (5) PT1301201E (cg-RX-API-DMAC7.html)
SI (3) SI3449934T1 (cg-RX-API-DMAC7.html)
TW (1) TWI280882B (cg-RX-API-DMAC7.html)
WO (1) WO2002005841A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416492C (en) * 2000-07-18 2008-04-29 Duke University Treatment of glycogen storage disease type ii
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
CA2723412A1 (en) * 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
HUE025212T2 (en) 2008-07-08 2016-03-29 Univ Duke A method for treating glycogen storage disease
WO2010148253A2 (en) 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
CA3209821A1 (en) * 2013-05-15 2014-11-20 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
BR112017005810A2 (pt) 2014-09-30 2018-02-27 Amicus Therapeutics Inc alfa-glucosidase ácida altamente potente com carboidratos melhorados
JP6821192B2 (ja) * 2015-05-07 2021-01-27 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
MA44747A (fr) * 2015-08-31 2019-03-06 Univ Duke Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
IL299470A (en) 2015-12-30 2023-02-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
PE20190127A1 (es) 2016-03-30 2019-01-17 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
CA3019427A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
LT3624831T (lt) 2017-05-15 2023-07-10 Amicus Therapeutics, Inc. Rekombinantinė žmogaus rūgštinė alfa-glukozidazė
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ATE410506T1 (de) * 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
CA2416492C (en) * 2000-07-18 2008-04-29 Duke University Treatment of glycogen storage disease type ii
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
US20100254966A1 (en) 2010-10-07
US20160184410A1 (en) 2016-06-30
US20180185457A1 (en) 2018-07-05
TWI280882B (en) 2007-05-11
PT2767291T (pt) 2016-10-25
PT1782825E (pt) 2014-11-04
US7056712B2 (en) 2006-06-06
JP5792774B2 (ja) 2015-10-14
EP3449934A1 (en) 2019-03-06
HK1197656A1 (en) 2015-02-06
CA2416492C (en) 2008-04-29
AU2001271941B2 (en) 2007-03-01
PT1301201E (pt) 2007-03-30
US9370556B2 (en) 2016-06-21
JP2016056206A (ja) 2016-04-21
ES2277931T3 (es) 2007-08-01
PT3108895T (pt) 2018-12-18
US20120058132A1 (en) 2012-03-08
HK1054690A1 (en) 2003-12-12
DE60126947T2 (de) 2007-10-31
SI2767291T1 (sl) 2016-11-30
JP2018199721A (ja) 2018-12-20
ES2700865T3 (es) 2019-02-19
LT3449934T (lt) 2020-08-10
SI3108895T1 (sl) 2019-01-31
DE60126947D1 (de) 2007-04-12
JP2020019822A (ja) 2020-02-06
EP3108895B1 (en) 2018-09-19
HK1103363A1 (en) 2007-12-21
EP3449934B1 (en) 2020-05-20
ATE355075T1 (de) 2006-03-15
CA2416492A1 (en) 2002-01-24
US9907839B2 (en) 2018-03-06
EP2767291A3 (en) 2014-10-08
US8900552B2 (en) 2014-12-02
JP2017137357A (ja) 2017-08-10
JP2004503598A (ja) 2004-02-05
MXPA03000474A (es) 2003-10-06
AU7194101A (en) 2002-01-30
EP1301201A1 (en) 2003-04-16
WO2002005841A1 (en) 2002-01-24
US20020110551A1 (en) 2002-08-15
JP6163216B2 (ja) 2017-07-12
EP2767291B1 (en) 2016-09-14
DK3108895T3 (en) 2018-11-26
PT3449934T (pt) 2020-06-25
AU2010200487A1 (en) 2010-03-04
EP2767291A2 (en) 2014-08-20
JP2014185187A (ja) 2014-10-02
ES2523024T3 (es) 2014-11-20
US20150004152A1 (en) 2015-01-01
LT2767291T (lt) 2016-11-25
LT3108895T (lt) 2018-11-26
BR0113006A (pt) 2004-10-19
JP2013231081A (ja) 2013-11-14
JP5113312B2 (ja) 2013-01-09
DK1782825T3 (da) 2014-11-03
CY1120977T1 (el) 2019-12-11
US10792341B2 (en) 2020-10-06
ES2799882T3 (es) 2020-12-22
JP2018002749A (ja) 2018-01-11
EP3108895A1 (en) 2016-12-28
US20080175833A1 (en) 2008-07-24
EP1301201B1 (en) 2007-02-28
CY1123084T1 (el) 2021-10-29
DK1301201T3 (da) 2007-04-02
DK2767291T3 (en) 2016-12-05
US20050123531A1 (en) 2005-06-09
DK3449934T3 (da) 2020-06-29
ES2599401T3 (es) 2017-02-01
JP2012006953A (ja) 2012-01-12
JP2008081507A (ja) 2008-04-10
US20210169996A1 (en) 2021-06-10
US20130195834A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2005089426A3 (en) Method of treating sepsis
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2002051404A8 (fr) Compositions orales
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
EP1782825A3 (en) Treatment of glycogen storage diseases type II
UA29106A (uk) Спосіб лікування вібраційної хвороби
UA31369A (uk) Спосіб покращання кровотоку пілородуоденальної зони